This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXPositive Net Change
biotechs cancer cannabis earnings-preview marijuana medical
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZPositive Net Change CRBPNo Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?
by Sundeep Ganoria
Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.
JAZZPositive Net Change KNSAPositive Net Change CRDLPositive Net Change
biotechs marijuana medical pot-stocks
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZPositive Net Change HRMYPositive Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?
by Sundeep Ganoria
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
JAZZPositive Net Change TLRYPositive Net Change
biotechs marijuana medical pot-stocks
Best & Worst ETF Zones of Q1
by Sweta Killa
We have highlighted three ETFs, each from the best and worst-performing zones in the first quarter of 2025.
EPOLNegative Net Change SGDMPositive Net Change WGMINegative Net Change WEEDNegative Net Change EETHNegative Net Change BABOPositive Net Change
bitcoin etfs gold marijuana
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCNo Net Change ACBNegative Net Change OGINegative Net Change
cannabis healthcare marijuana marijuana-stocks medical
IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.
RHPPositive Net Change IIPRNegative Net Change PKPositive Net Change
cannabis finance marijuana reit
Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?
by Moumita C. Chattopadhyay
With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?
PLDPositive Net Change TRNONegative Net Change IIPRNegative Net Change
cannabis finance marijuana marijuana-stocks reit
Top & Flop ETFs of 2024
by Sweta Killa
We have highlighted three ETFs each from the best and worst-performing zones in 2024.
TSLAPositive Net Change ARGTPositive Net Change GBTCNegative Net Change MAGSNegative Net Change BDRYPositive Net Change WEEDNegative Net Change ILITNegative Net Change
bitcoin etfs marijuana tech-stocks